Back to News
Market Impact: 0.35
Eli Lilly Shares Surge on Raised Sales Forecast
Source: Bloomberg
Corporate Guidance & OutlookHealthcare & BiotechCompany Fundamentals
Eli Lilly raised its full-year sales forecast as demand for its obesity and diabetes drugs continues to surge. The report also discusses implications for Novo Nordisk but provides no specific forecast figures or details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
LLY0.70
More News
- Alphabet’s stock has worst day in over 20 years, dragging the S&P 500 to first loss in four days
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
- West Pharma earnings show it's more than a GLP-1 play. Why we see more upside
- Lilly’s obesity drug strength fuels record rally, Wall Street optimism
- Stocks making the biggest moves midday: ADT, Alphabet, Caterpillar, Eli Lilly, Chipotle & more
- Cramer sees opportunity amid tech turmoil and predicts a holiday win for FedEx